Seres Posts $16.3M Q3 Loss, Pivots SER-155 Toward irEC Prevention With Cash Through Q1 2027
MCRB is trading near its 52-week low of $1.675 (6.9% above the low).
Summary
Seres reported a $16.3 million third-quarter loss and held $17.5 million in cash, enough to fund operations only through Q1 2027. The company also said it will push SER-155 into an irEC prevention study, contingent on funding, with an FDA design submission planned for Q1 2027.
Key Events · Earnings and Guidance · MCRB
-
Q3 Loss Widens to $16.3M
The net loss was $16.3 million for Q3 2026, versus net income of $8.2 million a year earlier, when a $25 million Nestlé installment was booked as a gain on sale. R&D fell to $5.6 million from $12.6 million, and G&A to $5.4 million from $9.5 million.
-
Cash Runs Out in Q1 2027
Cash and cash equivalents stood at $17.5 million on September 30, 2026. Counting the $12.5 million Nestlé payment received in October, management projects funding operations only through Q1 2027, excluding any partnership or other capital.
-
SER-155 Pivots to irEC Prevention
Seres will design a prophylactic study in patients starting checkpoint inhibitor therapy, with a dose-optimization component, building on the investigator-sponsored trial in which 12 of 15 participants (80%) achieved an immunosuppressive-free clinical response at Day 15. The study is dependent on funding.
-
FDA Design Submission Set for Q1 2027
The company expects to submit the proposed irEC study design to the FDA in the first quarter of 2027 and engage with the agency afterward; potential endpoints include incidence of irEC, ICI administration and safety.
Analysis · MCRB · Life Sciences
The runway is the story here: Seres lost $16.3 million in the third quarter and ended September with $17.5 million in cash, which management says funds operations only through the first quarter of 2027, leaving roughly two quarters before a financing or partnership is needed. Against that backdrop, the company is redirecting SER-155 toward preventing immune checkpoint inhibitor-related enterocolitis, a far larger patient pool than the transplant indication, though the study is explicitly 'dependent on funding' and the FDA design submission is not planned until Q1 2027. Cost cuts and cash inflows help at the margin: a $5.7 million impairment on the vacated Cambridge lease and the completed $25 million Nestlé milestone buy-out, but neither changes the runway math. Near term, capital rather than clinical data will drive the story.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCRB was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $1.68 to $29.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.